Who are Moxifloxacin or Levofloxacin's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Moxifloxacin HCl 0.5%, Moxifloxacin (Topical), Intracameral Moxifloxacin 0.1%, moxifloxacin 0.5% eye drops, Gatifloxacin 0.3%, Experimental: Active "I-Reconstruction" Therapy.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/moxifloxacin-or-levofloxacin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Moxifloxacin or Levofloxacin — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Moxifloxacin or Levofloxacin (Moxifloxacin or Levofloxacin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: fluoroquinolone. Area: Infectious Diseases.

phase 3 fluoroquinolone DNA gyrase and topoisomerase IV Infectious Diseases Small molecule Live · refreshed every 30 min

Target snapshot

Moxifloxacin or Levofloxacin (Moxifloxacin or Levofloxacin) — UMC Utrecht. Moxifloxacin and Levofloxacin are broad-spectrum antibiotics that inhibit DNA gyrase and topoisomerase IV, enzymes critical for bacterial DNA replication.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Moxifloxacin or Levofloxacin TARGET	Moxifloxacin or Levofloxacin	UMC Utrecht	phase 3	fluoroquinolone	DNA gyrase and topoisomerase IV
Moxifloxacin HCl 0.5%	Moxifloxacin HCl 0.5%	Carolina Eyecare Physicians, LLC	marketed	Fluoroquinolone antibiotic	Bacterial DNA gyrase and topoisomerase IV
Moxifloxacin (Topical)	Moxifloxacin (Topical)	University of California, San Francisco	marketed	Fluoroquinolone antibiotic	Bacterial DNA gyrase and topoisomerase IV
Intracameral Moxifloxacin 0.1%	Intracameral Moxifloxacin 0.1%	Suzan A Rattan	marketed	Fluoroquinolone antibiotic	Bacterial DNA gyrase and topoisomerase IV
moxifloxacin 0.5% eye drops	moxifloxacin 0.5% eye drops	Allergan	marketed	Fluoroquinolone antibiotic	Bacterial DNA gyrase and topoisomerase IV
Gatifloxacin 0.3%	Gatifloxacin 0.3%	Innovative Medical	marketed	Fluoroquinolone	DNA gyrase and topoisomerase IV
Experimental: Active "I-Reconstruction" Therapy	Experimental: Active "I-Reconstruction" Therapy	International Association Psychosomatics And Health Therapy	marketed	Fluoroquinolone	DNA gyrase and topoisomerase IV

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (fluoroquinolone class)

Centers for Disease Control and Prevention · 1 drug in this class
Dr. Reddy's Laboratories Limited · 1 drug in this class
UMC Utrecht · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Moxifloxacin or Levofloxacin — Competitive Intelligence Brief. https://druglandscape.com/ci/moxifloxacin-or-levofloxacin. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab